D. Allen Annis, Ph.d.
Vice President, Biophysical and Analytical Technol
Biophysical and Analytical Technology
Aileron Therapeutics
United States of America
Biography
Allen Annis has served as our Senior Director of Biophysical and Analytical Technologies since November of 2007. He was previously Director of Technology Development at the Schering-Plough Research Institute in Cambridge, MA, and prior to that he was Vice President of New Technologies at NeoGenesis Pharmaceuticals, which was acquired by Schering in 2005. While at NeoGenesis, Dr. Annis co-developed its core drug discovery platform, the affinity selection-mass spectrometry-based Automated Ligand Identification System (ALIS). Dr. Annis authored several patents and publications that describe the ALIS technology, and invented many novel techniques that use ALIS to study protein-drug interactions. Dr. Annis received his B.S. in chemistry from the Georgia Institute of Technology and received his Ph.D. in chemistry from Harvard University.
Research Interest
Dr. Annis co-developed its core drug discovery platform, the affinity selection-mass spectrometry-based Automated Ligand Identification System (ALIS).
